Friday’s Midday Movers: ImmunoCellular Therapeutics (IMUC), Rosetta Genomics Ltd (ROSG), Advaxis (ADXS), Idera (IDRA), Anthera Pharmaceuticals (ANTH)

By Carrie Williams

So far Friday, December 14, NASDAQ is down -1% and the S&P is down -1.41%. Here are this morning’s most active stocks: ImmunoCellular Therapeutics (IMUCResearch Report), Rosetta Genomics Ltd (ROSGResearch Report), Advaxis (ADXSResearch Report), Idera (IDRAResearch Report) and Anthera Pharmaceuticals (ANTHResearch Report).

ImmunoCellular Therapeutics is up 34.36% in midday trading to $0.02. Shares opened today at $0.02. The company has a 52-week low of $0.02 and a 52-week high of $0.00.

Rosetta Genomics Ltd is down -15% in midday trading to $0.00. Shares opened today at $0.00. The company has a 52-week low of $0.00 and a 52-week high of $0.00.

Advaxis is down -13.19% in midday trading to $0.25. Shares opened today at $0.28. The company has a 52-week low of $0.22 and a 52-week high of $0.00. On the Street’s front, the average 12-month analyst price target for the stock is $2.00, marking a 605.47% potential upside from current levels. In a report issued on November 6, H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on ADXS, with a price target of $2, which represents a potential upside of 605% from where the stock is currently trading.

See today’s analyst top recommended stocks >>

Idera is down -9.27% in midday trading to $5.34. Shares opened today at $5.88. The company has a 52-week low of $5.09 and a 52-week high of $0.00. On the Street’s front, the average 12-month analyst price target for the stock is $21.33, marking a 262.76% potential upside from current levels. In a report issued on November 8, H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on IDRA, with a price target of $18, which implies an upside of 206% from current levels.

Anthera Pharmaceuticals is up 9.09% in midday trading to $0.04. Shares opened today at $0.03. The company has a 52-week low of $0.01 and a 52-week high of $0.00.

See today’s analyst top recommended stocks >>

Trending Stocks Based on Insider Activity >>